The shrinking or disappearing observed treatment effect

Pharmaceutical Statistics

Volumn 13, Issue 5, 2014, Pages 277-280

  Chuang Stein, Christy ^a   Kirby, Simon ^b  

^a PFIZER INC   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Overestimation; Regression to the mean; Shrinkage

Indexed keywords

CONCEPTUAL FRAMEWORK; DEVELOPMENTAL STAGE; DIAGNOSTIC TEST; MEDICAL LITERATURE; MEDICAL SOCIETY; PROBABILITY; PUBLICATION; REVIEW; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); EMPIRICAL RESEARCH; HUMAN; PROCEDURES; STANDARDS; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; EMPIRICAL RESEARCH; HUMANS; TREATMENT OUTCOME;

EID: 84907601987     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1633     Document Type: Review

References (12)

1. Pereira TV, Horwitz RI, Ioannidis JPA. Empirical evaluation of very large treatment effects of medical intervention. Journal of the American Medical Association 2012; 308(16):1676-1684.
2. Lee SJ, Zelen M. Clinical trials and sample size consideration: another perspective. Statistical Science 2000; 15(2):95-110.
3. Zhang JJ, BlumenthalGM, He K, Tang S, Cortazar P, Sridhara R. Over-estimation of the effect size in group sequential trials. Clinical Cancer Research 2012; 18(18):4872-4876.
4. Emerson SS, Fleming TR. Parameter estimation following sequential hypothesis testing. Biometrika 1990; 77:875-892.
5. Pinheiro JC, DeMets DL. Estimating and reducing bias in group sequential designs with Gaussian independent structure. Biometrika 1997; 84:831-843.
6. Kirby S, Burke J, Chuang-Stein C, Sin C. Discounting phase 2 results when planning phase 3 clinical trials. Pharmaceutical Statistics 2012; 11:373-385.
7. Wang SJ, Hung HMJ, O'Neill RT. Adapting the sample size planning of a phase III trial based on phase II data. Pharmaceutical Statistics 2006; 5:85-97.
8. Kirby S. Discounting Phase 2 Results When Planning Phase 3 Clinical Trials. Presentation at PSI One Day meeting on Predictive Inference: Can this reduce late stage failures? Stevenage, UK, April 18, 2013. Available at: http://psiweb.org/docs/default-source/resources/psisubgroups/scientific/2013/predictive-inference-course-slides-18-april-2013/simon-kirby-slides.ppt?sfvrsn=0.
9. Zhang J. Evaluating Regression-to-the-Mean of Treatment Effect From Phase 2 to Phase 3, Presentation at the ENAR Spring Meeting: Baltimore MD, March 18, 2014. Available at: http://www.enar.org/meetings2014/2014-Abstracts-022814.pdf.
10. O'Hagan A, Stevens JW, Campbell MJ. Assurance in clinical trial design. Pharmaceutical Statistics 2005; 4:187-201.
11. Chuang-Stein C, Kirby S, French J, Kowalski K, Marshall S, Smith MK, Bycott P, Beltangady M. A quantitative approach for making Go/No-Go decisions in drug development. Drug Information Journal 2011; 45:187-202.
12. Ioannidis JPA. Why most discovered true associations are inflated? Epidemiology 2008; 19(5):640-648.